Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Shalu Pahuja"'
Autor:
Monica K. Malhotra, Shalu Pahuja, Brian F. Kiesel, Leonard J. Appleman, Fei Ding, Yan Lin, Hussein A. Tawbi, Ronald G. Stoller, James J. Lee, Chandra P. Belani, Alice P. Chen, Vincent L. Giranda, Stacie Peacock Shepherd, Leisha A. Emens, S. Percy Ivy, Edward Chu, Jan H. Beumer, Shannon Puhalla
Publikováno v:
Breast Cancer Research and Treatment. 198:487-498
Autor:
Thomas J. George, Greg Yothers, Samuel A. Jacobs, Gene Grant Finley, James Lloyd Wade, Caio Max Sao Pedro Rocha Lima, Jeffrey Scott Rose, Shalu Pahuja, Anuradha Krishnamurthy, John C. Krauss, Melvin Deutsch, Jesus C. Fabregas, James J. Lee, Carmen Joseph Allegra, Norman Wolmark
Publikováno v:
Journal of Clinical Oncology. 40:99-99
99 Background: Although immunotherapy shows no benefit in microsatellite stable (MSS) colorectal cancer, preclinical models suggest that radiotherapy (RT) can enhance neoantigen presentation, modulate the microenvironment, and improve the likelihood
Autor:
Nancy E. Davidson, Kandace P. McGuire, Priya Rastogi, Rachel C. Jankowitz, Adam Brufsky, Shalu Pahuja, Barry C. Lembersky, Shannon Puhalla
Publikováno v:
Cancer Research. 75:P3-11
Background: More than half of pts with TNBC do not achieve a pCR after NAC, which carries a poor prognosis. It is unclear whether these patients respond to subsequent therapies on relapse. We sought to determine the time to progression (TTP) on subse
Publikováno v:
Journal of Clinical Oncology. 37:e15574-e15574
e15574 Background: Optimal multimodality treatment followed by surgical resection results in cure for less than half of patients with operable adenocarcinoma of the lower esophagus or GEJ. The current standard of care is either neoadjuvant chemoradia
Publikováno v:
Journal of Surgical Oncology. 104:386-390
Clinically detectable regional lymph node melanoma metastasis (AJCC stage IIIB-C) carries a risk of relapse and death that approaches 70% at 5 years. Surgical management is the cornerstone of therapy, with postoperative adjuvant therapy utilizing hig
Autor:
Hannah Ludwick, Sidra Najeeb, Shalu Pahuja, Sijin Wen, Gerald M Higa, Rajesh R. Nair, Miklos L Auber, Zelia Ramone Karema Bowman, Albina Kibirova
Publikováno v:
Journal of Clinical Oncology. 36:e15695-e15695
e15695Background: The outcome for patients with high-risk loco-regional colorectal cancer (CRC) remains unsatisfactory despite the use of adjuvant chemotherapy. Based on the SEER data, the worst su...
Publikováno v:
Journal of surgical oncology. 104(4)
Clinically detectable regional lymph node melanoma metastasis (AJCC stage IIIB-C) carries a risk of relapse and death that approaches 70% at 5 years. Surgical management is the cornerstone of therapy, with postoperative adjuvant therapy utilizing hig
Publikováno v:
Journal of Clinical Oncology. 33:e17626-e17626
e17626 Background: Clinical trials are increasingly requiring tissue biopsies in order to further our understanding of tumor biology and mechanisms of drug sensitivity and resistance. Several studi...
Autor:
Stacie Peacock Shepherd, Jan H. Beumer, Shannon Puhalla, James J. Lee, Fei Ding, Edward Chu, Shalu Pahuja, Jing Yu, Chandra P. Belani, Ronald G. Stoller, Hussein Tawbi, Yan Lin, Leonard Joseph Appleman, Vincent L. Giranda, Alice P. Chen
Publikováno v:
Journal of Clinical Oncology. 33:1015-1015
1015 Background: Veliparib (ABT-888) is an oral, potent small molecule inhibitor of poly-ADP-ribose polymerase (PARP). The combination of veliparib (V) with carboplatin (C) and paclitaxel (P) dosed...
Autor:
Shannon Puhalla, Leonard Joseph Appleman, Chandra P. Belani, Shalu Pahuja, Edward Chu, Alice P. Chen, Jan H. Beumer
Publikováno v:
Journal of Clinical Oncology. 33:170-170
170 Background: Male BRCA mutation carriers have a 2-8-fold increased risk of prostate cancer when compared to the general population, and up to 3% of patients (pts) with prostate cancer carry an inherited mutation in BRCA1 or 2. The therapeutic impl